Klebsiella pneumoniae Infections - Pipeline Review, H1 2020

April 2020 | 128 pages | ID: KB3F22644AFEN
Global Markets Direct

Abstracts

Klebsiella pneumoniae Infections - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Klebsiella pneumoniae Infections - Pipeline Review, H1 2020, provides an overview of the Klebsiella pneumoniae Infections (Infectious Disease) pipeline landscape.

Klebsiella pneumoniae is a Gram-negative bacteria. A Klebsiella pneumoniae infection is caused when the organism is able to enter the lungs. A Klebsiella pneumoniae infection is very common in patients with underlying diseases like diabetes, chronic lung diseases and chronic alcoholics. It is mostly a nosocomial infection that occurs in hospitalized patients with weakened immune system. Symptoms include necrosis, inflammation, hemorrhage, chills, dizziness, high fever, head ache and chest pain. Treatment includes antibiotics and hygiene lifestyle.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Klebsiella pneumoniae Infections - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Klebsiella pneumoniae Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Klebsiella pneumoniae Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Klebsiella pneumoniae Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Preclinical and Discovery stages are 1, 27 and 12 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 6 and 2 molecules, respectively.

Klebsiella pneumoniae Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Klebsiella pneumoniae Infections (Infectious Disease).
• The pipeline guide reviews pipeline therapeutics for Klebsiella pneumoniae Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Klebsiella pneumoniae Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Klebsiella pneumoniae Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Klebsiella pneumoniae Infections (Infectious Disease)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Klebsiella pneumoniae Infections (Infectious Disease).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Klebsiella pneumoniae Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Klebsiella pneumoniae Infections - Overview
Klebsiella pneumoniae Infections - Therapeutics Development
Klebsiella pneumoniae Infections - Therapeutics Assessment
Klebsiella pneumoniae Infections - Companies Involved in Therapeutics Development
Klebsiella pneumoniae Infections - Drug Profiles
Klebsiella pneumoniae Infections - Dormant Projects
Klebsiella pneumoniae Infections - Discontinued Products
Klebsiella pneumoniae Infections - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Klebsiella pneumoniae Infections, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Klebsiella pneumoniae Infections - Pipeline by ABAC Therapeutics SA, H1 2020
Klebsiella pneumoniae Infections - Pipeline by Acies Bio doo, H1 2020
Klebsiella pneumoniae Infections - Pipeline by AEON Medix Inc, H1 2020
Klebsiella pneumoniae Infections - Pipeline by Affinivax Inc, H1 2020
Klebsiella pneumoniae Infections - Pipeline by Akthelia Pharmaceuticals Ltd, H1 2020
Klebsiella pneumoniae Infections - Pipeline by Appili Therapeutics Inc, H1 2020
Klebsiella pneumoniae Infections - Pipeline by Armata Pharmaceuticals Inc, H1 2020
Klebsiella pneumoniae Infections - Pipeline by BB200 LLC, H1 2020
Klebsiella pneumoniae Infections - Pipeline by Bugworks Research India Pvt Ltd, H1 2020
Klebsiella pneumoniae Infections - Pipeline by Celdara Medical LLC, H1 2020
Klebsiella pneumoniae Infections - Pipeline by ContraFect Corp, H1 2020
Klebsiella pneumoniae Infections - Pipeline by Debiopharm International SA, H1 2020
Klebsiella pneumoniae Infections - Pipeline by Eligochem Ltd, H1 2020
Klebsiella pneumoniae Infections - Pipeline by EnBiotix Inc, H1 2020
Klebsiella pneumoniae Infections - Pipeline by F. Hoffmann-La Roche Ltd, H1 2020
Klebsiella pneumoniae Infections - Pipeline by Fedora Pharmaceuticals Inc, H1 2020
Klebsiella pneumoniae Infections - Pipeline by Forge Therapeutics Inc, H1 2020
Klebsiella pneumoniae Infections - Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2020
Klebsiella pneumoniae Infections - Pipeline by Melinta Therapeutics Inc, H1 2020
Klebsiella pneumoniae Infections - Pipeline by Microbiotix Inc, H1 2020
Klebsiella pneumoniae Infections - Pipeline by Neoculi Pty Ltd, H1 2020
Klebsiella pneumoniae Infections - Pipeline by Nosopharm SAS, H1 2020
Klebsiella pneumoniae Infections - Pipeline by Oryn Therapeutics, H1 2020
Klebsiella pneumoniae Infections - Pipeline by Peptilogics Inc, H1 2020
Klebsiella pneumoniae Infections - Pipeline by Phico Therapeutics Ltd, H1 2020
Klebsiella pneumoniae Infections - Pipeline by ReAlta Life Sciences Inc, H1 2020
Klebsiella pneumoniae Infections - Pipeline by RemAb Therapeutics SL, H1 2020
Klebsiella pneumoniae Infections - Pipeline by Shionogi & Co Ltd, H1 2020
Klebsiella pneumoniae Infections - Pipeline by Soligenix Inc, H1 2020
Klebsiella pneumoniae Infections - Pipeline by Spero Therapeutics Inc, H1 2020
Klebsiella pneumoniae Infections - Pipeline by Summit Therapeutics Plc, H1 2020
Klebsiella pneumoniae Infections - Pipeline by Syntiron LLC, H1 2020
Klebsiella pneumoniae Infections - Pipeline by VaxNewMO LLC, H1 2020
Klebsiella pneumoniae Infections - Pipeline by Vaxxilon AG, H1 2020
Klebsiella pneumoniae Infections - Pipeline by Venus Medicine Research Center, H1 2020
Klebsiella pneumoniae Infections - Dormant Projects, H1 2020
Klebsiella pneumoniae Infections - Dormant Projects, H1 2020 (Contd..1), H1 2020
Klebsiella pneumoniae Infections - Dormant Projects, H1 2020 (Contd..2), H1 2020
Klebsiella pneumoniae Infections - Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Klebsiella pneumoniae Infections, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020

COMPANIES MENTIONED

ABAC Therapeutics SA
Acies Bio doo
AEON Medix Inc
Affinivax Inc
Akthelia Pharmaceuticals Ltd
Appili Therapeutics Inc
Armata Pharmaceuticals Inc
BB200 LLC
Bugworks Research India Pvt Ltd
Celdara Medical LLC
ContraFect Corp
Debiopharm International SA
Eligochem Ltd
EnBiotix Inc
F. Hoffmann-La Roche Ltd
Fedora Pharmaceuticals Inc
Forge Therapeutics Inc
Kyorin Pharmaceutical Co Ltd
Melinta Therapeutics Inc
Microbiotix Inc
Neoculi Pty Ltd
Nosopharm SAS
Oryn Therapeutics
Peptilogics Inc
Phico Therapeutics Ltd
ReAlta Life Sciences Inc
RemAb Therapeutics SL
Shionogi & Co Ltd
Soligenix Inc
Spero Therapeutics Inc
Summit Therapeutics Plc
Syntiron LLC
VaxNewMO LLC
Vaxxilon AG
Venus Medicine Research Center